Department of Clinical Neuroscience, Division of Neurology, Karolinska Institutet, Huddinge, Sweden.
Acta Neurol Scand. 2010 Mar;121(3):154-60. doi: 10.1111/j.1600-0404.2009.01285.x. Epub 2010 Jan 6.
To explore the occurrence and reasons for stopping, switching or continuing first prescribed interferon-beta therapy in patients with multiple sclerosis in Sweden, with respect to demographic, clinical and/or therapy-related factors.
A retrospective study reviewing the medical charts of 259 patients with multiple sclerosis, comparing patients continuing therapy for at least 3 years with those switching or stopping therapy.
Sixty 9% stopped (15%), or switched (54%), interferon-beta therapy within 3 years. Stoppers had longer disease duration before starting therapy (P = 0.002), less frequently relapsing-remitting multiple sclerosis (P = 0.046), and more often Expanded Disability Status Scale scores 6-9.5 (P = 0.045) compared to Switchers. The most common reasons for switching/stopping therapy were perceived lack of effect and side-effects.
Adherence to initial immune-modulating therapy is low; identification of patients at higher risk of stopping therapy and provision of adequate support are essential.
探讨瑞典多发性硬化症患者停止、转换或继续首次处方干扰素-β治疗的发生原因和原因，考虑人口统计学、临床和/或治疗相关因素。
回顾性研究了 259 名多发性硬化症患者的病历，将至少连续治疗 3 年的患者与转换或停止治疗的患者进行了比较。
69%的患者（15%）在 3 年内停止（15%）或转换（54%）干扰素-β治疗。停止治疗的患者在开始治疗前的疾病持续时间更长（P = 0.002），复发缓解型多发性硬化症的频率较低（P = 0.046），扩展残疾状况量表评分 6-9.5 的频率更高（P = 0.045）与 Switchers。转换/停止治疗的最常见原因是认为缺乏疗效和副作用。
初始免疫调节治疗的依从性较低；识别有停药风险的患者并提供充分的支持至关重要。
Zotero 插件